ARMATA PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
ARMATA PHARMACEUTICALS, INC. (ARMP) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $31.00 thousand as of 2018-12-31, per its 10-K filed 2019-03-25.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2019-03-25
- 2018-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $31.00K.
- 2017-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $31.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2018-12-31 | $31.00K 10-K · filed 2019-03-25 |
| 2017-12-31 | $31.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |